Orthofix Medical Inc (OFIX) FinancialsOFIXOrthofix Medical Inc

Orthofix Medical Inc. (OFIX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Spinal Implants, accounting for 53.9% of total sales, equivalent to $106.08M. Another important revenue stream is Bone Growth Therapies. Understanding this composition is critical for investors evaluating how OFIX navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Orthofix Medical Inc. maintains a gross margin of 69.55%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1.62%, while the net margin is -7.49%. These profitability ratios, combined with a Return on Equity (ROE) of -13.91%, provide a clear picture of how effectively OFIX converts its operational activities into shareholder value.

In the context of the broader market, OFIX competes directly with industry leaders such as MYGN and SI. With a market capitalization of $382.07M, it holds a significant position in the sector. When comparing efficiency, OFIX's gross margin of 69.55% stands against MYGN's 66.60% and SI's 71.81%. Such benchmarking helps identify whether Orthofix Medical Inc. is trading at a premium or discount relative to its financial performance.

The company has shown mixed financial performance, with a gross margin of 69.55% in Q2 2026, indicating strong cost management relative to revenue. However, it has consistently reported net losses, including a net income of -$15.798 million in Q2 2026, which raises concerns about its long-term viability. Revenue for Q2 2026 was $210.93 million, reflecting a 3.8% year-over-year increase, but the company has cut its revenue guidance for 2026, which could impact investor sentiment.